期刊文献+

三氧化二砷联合5-FU抑制结肠癌干细胞的研究 被引量:1

The evaluation of 5-FU in combination with As_2O_3 for colorectal cancer treatment
下载PDF
导出
摘要 目的探讨三氧化二砷(As2O3)联合5-氟尿嘧啶(5-FU)对结肠癌干细胞的抑制作用。方法将结肠癌干细胞分成As2O3干预组、5-FU干预组、联合干预组和PBS阴性对照组。采用MTT实验考察联合干预对结肠癌干细胞的毒性。用结肠癌干细胞构建肿瘤球模型,考察联合干预对结肠癌干细胞肿瘤球的生长抑制作用。采用流式细胞技术考察联合干预诱导肿瘤干细胞凋亡的能力。制备结肠癌的动物模型,考察联合干预对结肠癌荷瘤小鼠肿瘤的抑制作用。结果与PBS组和单独给药组相比,联合干预组对结肠癌干细胞具有更强的细胞毒性,差异具有统计学意义(P<0.01)。细胞凋亡实验结果表明,联合干预能够促进肿瘤干细胞凋亡,差异具有统计学意义(P<0.01)。肿瘤球给药7 d后5-FU干预组、As2O3干预组和联合干预组分别使肿瘤体积减小到原体积的71%、85%和44%,PBS组肿瘤球体积增大1.48倍,差异具有统计学意义(P<0.01);体内治疗实验结果显示,PBS组、As2O3干预组和5-FU干预组小鼠肿瘤体积成长分别变为给药前肿瘤体积的2.55倍、2.13倍和1.54倍,而联合干预组肿瘤体积变化为原体积的1.27倍,联合干预组与环靶明干预组或5-FU干预组间差异具有统计学意义(P<0.01)。结论 As2O3联合5-FU能够有效抑制结肠癌干细胞的增殖,5-FU联合As2O3是一种潜在的结肠癌干细胞治疗方法。 Objective To evaluate the effect of 5-FU combined with As2O3 the inhibition of colorectal cancer stem cells (LSCs).Methods The colorectal cancer stem cells were divided into four groups:As2O3 group,5-FU group,As2O3 + 5-FU group and PBS group.The MTT assay was used to evaluate the anti-proliferation efficiency of As2O3 combined with 5-FU.Flow cytometry was used to evaluate the LSCs induced apoptosis by 5-FU and As2O3.Tumor spheroids were also used to evaluate anti-tumor ability of 5-FU combined with As2O3.LSCs were xenografted in mice to establish the animal model,which were used to evaluate the effect of anti-tumor.Results Compared with PBS group,5-FU group and As2O3 group,the As2O3 + 5-FU group could inhibit the growth of LSCs effectively (P < 0.05).The 5-FU combined with As2O3 could induced the apoptosis of LSCs more effective than As2O3 alone.The As2O3 + 5-FU group could significantly inhibit the growth of tumor.Conclusion The As2O3 can inhibit the growth of colorectal cancer stem cells,the As2O3 + 5-FU can induce the apoptosis of LSCs,and the combination of As2O3 and 5-FU may be a potentially effective treatment for colorectal cancer.
出处 《胃肠病学和肝病学杂志》 CAS 2014年第6期645-647,共3页 Chinese Journal of Gastroenterology and Hepatology
关键词 5-氟尿嘧啶 三氧化二砷 结肠癌 肿瘤干细胞 5-FU As2O3 Colorectal cancer Cancer stem cells
  • 相关文献

参考文献11

  • 1Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea-a para- digm shift [J]. Cancer Res, 2006, 66(4) : 1883-1890.
  • 2Mannelli G, Gallo O. Cancer stem cells hypothesis and stem cells in bead and neck cancers I J ]. Cancer Treat Rev, 2012, 38 ( 5 ) : 515-539.
  • 3Lu J, Huang Y, Zhao W, et al. PEG-derivatized embelin as a nanomicel- lax carrier for delivery of paclitaxel to breast and prostate cancers [ J ]. Bio- materials, 2013, 34(5): 1591-1600.
  • 4Su J, Xu XH, Huang Q, et al. Identification of cancer stem-like CD44 + cells in human nasopharyngeal carcinoma cell line [ J]. Arch Med Res, 2011, 42(1) : 15-21.
  • 5Bhatavdekar JM, Patel DD, Chikhlikar PR, et al. Over expression of CD44: a useful independent predictor of prognosis in patients with colorectal carcinomas [J]. Ann Surg Oneol, 1998, 5(6) : 495-501.
  • 6曹洁,唐金海,侯梅.FOLFOX4方案治疗结直肠癌患者5-FU稳态血药浓度与不良反应的相关性研究[J].中华肿瘤防治杂志,2011,18(2):134-136. 被引量:17
  • 7Cassidy J, Saltz L, Twelves C, et al. Efficacy of capeeitabine versus 5- FU in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients [J]. Ann Oneol, 2011, 22(12): 2604-2609.
  • 8Ito K, Bernardi R, Morotti A, et al. PMI targeting eradicates quiescent leukaemia-initiating cells [ J ]. Nature, 2008, 453 ( 7198 ) : 1072-1078.
  • 9Horton S J, Huntly BJ. Recent advances in acute myeloid leukemia stem cell biology [J]. Haematologica, 2012, 97(7) : 966-974.
  • 10Ferretti E, Cocco C, Airoldi I, et al. Targeting aeute myeloid leuke- miacells with cytokines [ J]. J Leukoc Biol, 2012, 92 (3) : 567-575.

二级参考文献9

  • 1周志伟,王国强,万德森,潘志忠,李苏,陈功,廖海.二氢嘧啶脱氢酶活性与结直肠癌患者5-FU辅助化疗毒性关系的研究[J].癌症,2004,23(z1):1512-1516. 被引量:6
  • 2Zachariae R, duced nausea, Paulsen K, Mehlsen M, et al. and fatigue the Chemotherapy inrole of individual differences related to sensory perception and autonomic reactivity [J].Psychother Psychosom, 2007,76 (6) : 376 384.
  • 3Ciccolini J, Gross E, Dahan I., et al. Routine dihydropyrimidine dehydrogenase testing for anticipating 5 fluorouracil-related severe toxicities: hype or hope? [J]. Clin Colorectal Cancer, 2010,9(4) :224-228.
  • 4Mounier-Boutoille H, Boisdron Celle M, Cauchin E, et al. Le thal outcome of 5-fluorouracil infusion in a patient with a total DPD deficiency and a double DPYD and UTG1A1 gene mutation [J].Br J Clin Pharmacol, 2010,70(2) :280-283.
  • 5Hooived E A, van Kuilenburg A B, Haanen J B, et al. Severe toxicity after treatment with capeeitabine and fluorouracil due to partial dihydropyrimidine dehydrogenase deficiency[J].Ned Tijdschr Geneeskd, 2004,48(13) :626-628.
  • 6Tomiak A, Vincent M, Kocha W, et al. Standard dose (Mayo regimen) 5-fluorouracil and low dose folinic acid:prohibitive toxicity? [J]. Am J Clin Oncol,2000,23(1) :94-98.
  • 7Dahl O, Fluge O, Carlsen E,et al. Final results of a randomised phase Ⅲ study on adjuvant chemotherapy with 5-FU and levamisol in colon and rectum cancer stage Ⅱ and Ⅲ by the Norwegian Gastrointestinal Cancer Group[J]. Acta Oncol, 2009, 48(3): 368-376.
  • 8Meza-Junco J, Sawyer M B. Drug exposure: still an excellent bi omarker[J].Biomark Med ,2009,3(6) : 723-731.
  • 9Boisdron Celle M, Le Guellec C, Suivi Th4rapeutique, et al. Thera peutic drug monitoring of 5-fluorouracil after its administration in high-dose protocols[J].Therapie, 2010, 65(3): 171-176.

共引文献16

同被引文献14

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部